Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical segment achieved a revenue of CNY 4.751 billion, representing a year-on-year growth of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year increase of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] - Plant-based products, such as Qixue Kang Oral Liquid, reached sales of CNY 202 million, with a year-on-year growth of approximately 116.2% [2] Group 2: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 22 activated, enrolling 60 subjects [3] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled for Phase II trials [3] Group 3: Health Products Business Performance - The health products segment reported a revenue of CNY 3.442 billion in the first half of 2025, reflecting a year-on-year growth of 9.46% [4] - The segment focuses on a full-channel operation strategy, enhancing offline distribution capabilities and increasing online channel investments [4] - The oral care category, particularly gum care toothpaste, maintains and gradually expands its leading advantage, while anti-sensitivity toothpaste shows breakthrough growth [4] Group 4: Online Sales Performance - The pharmaceutical segment's online sales increased by over 20% year-on-year, with a GMV of CNY 254 million generated from 4.845 million visitors [5] - Yunnan Baiyao toothpaste holds the top market share in the domestic all-channel market, while Yangyuanqing shampoo ranked first in Tmall's domestic anti-hair loss category during the 2025 "618" shopping festival [5] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion [6] - The total cash dividend for 2024, including special dividends, amounted to CNY 23.98 per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, the company distributed a cash dividend of CNY 10.19 per 10 shares, totaling CNY 1.818 billion, with special dividends accounting for 50.05% of the net profit for the period [7]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [2] - Participants included representatives from CITIC Securities and Prudential Asset Management [2] - The meeting took place on November 21, 2025, at the Group's headquarters [2] Group 2: Purpose of the Meeting - The main objective was to understand the company's production and operational status [2] - The meeting involved direct communication with the company's board secretary and investor relations management [2]

Core Viewpoint - The Chinese traditional medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by rising flu cases and the performance of key stocks in the industry [1][2]. Group 1: Market Performance - As of November 24, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.68%, with a one-year dividend yield of 3.18% [1]. - Key component stocks such as Jiaying Pharmaceutical (002198) increased by 4.48%, Zhongsheng Pharmaceutical (002317) by 2.86%, and others also showed positive growth [1]. - The Zhongzheng Traditional Chinese Medicine ETF (159647) increased by 0.40%, with the latest price at 1 yuan [1]. Group 2: Flu Trends and Impact - The National Influenza Center reported that the ILI% in southern hospitals was 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [1]. - Northern hospitals reported an ILI% of 6.1%, also higher than the previous week and exceeding levels from the last three years [1][2]. - The rising flu positivity rates in both southern and northern regions are attributed to lower immunity against the H3N2 strain and an earlier onset of the flu season this year [2]. Group 3: Industry Outlook - The flu season for 2025-2026 is expected to peak higher than the previous year, leading to increased demand for respiratory infection-related products [2]. - The traditional Chinese medicine sector is anticipated to face short-term performance pressure but is expected to benefit from policies related to centralized procurement and basic medicine, as well as innovation-driven growth [2]. - The top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index account for 54.92% of the index, indicating a concentrated market structure [3].

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The demand for respiratory medications is expected to rise due to the increase in flu cases, with a reported 955 flu-like illness outbreaks, marking a 53.8% increase from the previous week [4]. - The market performance of the Traditional Chinese Medicine (TCM) sector showed a decline of 6.46% last week, ranking second among secondary pharmaceutical sectors [1]. - The TCM sector's Price-to-Earnings (PE) ratio (ttm) is 27.36X, down by 1.89X week-on-week, while the Price-to-Book (PB) ratio (lf) is 2.31X, down by 0.16X [2]. Market Performance - The TCM sector reported a closing index of 6419.16 points, down 6.46% for the week, while the overall pharmaceutical sector index fell by 6.88% [1][16]. - Among companies, *ST Changyao, Weikang Pharmaceutical, Jiangzhong Pharmaceutical, Yunnan Baiyao, and Dong'e Ejiao showed better performance, while Te Yi Pharmaceutical, Panlong Pharmaceutical, Zhendong Pharmaceutical, Yiling Pharmaceutical, and Enwei Pharmaceutical lagged [1]. Valuation Metrics - The TCM sector's PE ratio is at the 28.94% percentile since 2013, while the PB ratio is at the 5.93% percentile, indicating relatively low valuation compared to historical data [2]. Supply Chain Insights - The market for TCM raw materials is currently weak, with a price index of 224.73 points, reflecting a 0.3% decrease due to oversupply and inventory buildup [3]. Investment Recommendations - Three main investment themes are highlighted: 1. Price governance focusing on competitive advantages and innovation capabilities [5]. 2. Consumption recovery driven by macroeconomic improvement and aging population [5]. 3. State-owned enterprise reform, which is expected to enhance efficiency and performance [5]. Target Companies - Recommended companies include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products [9].

2020-2025年1-9月中国中成药产量统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：云南白药（000538）,同仁堂（600085）,片仔癀（600436）,白云山（600332）,太极集团 （600129）,东阿阿胶（000423）,九芝堂（000989）,贵州百灵（002424）,葵花药业（002737）,吉林敖 东（000623） 相关报告：智研咨询发布的《2026-2032年中国中成药行业发展形势分析及产业前景规划报告》 根据国家统计局数据显示：2025年9月中国中成药产量为16.9万吨，同比增长2.4%；2025年1-9月中国中 成药累计产量为132.2万吨，累计下降8.3%。 ...

证券之星消息，11月21日中药板块较上一交易日下跌2.09%，振东制药领跌。当日上证指数报收于 3834.89，下跌2.45%。深证成指报收于12538.07，下跌3.41%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300878 | 维康药业 | 28.18 | 0.64% | 5.47万 | | 1.52亿 | | 002317 | 众生药业 | 23.41 | 0.56% | 120.38万 | | 28.64亿 | | 600436 | 片仔瘦 | 176.20 | 0.14% | 2.05万 | | 3.62亿 | | 600771 | 广营远 | 19.41 | -0.36% | 9.93万 | | 1.94亿 | | 600535 | 天士力 | 15.20 | -0.39% | 12.65万 | | 1.92亿 | | 000538 | 云南白药 | 55.66 | -0.68% | 10.59万 | | 5.90亿 | | 600 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in Yunnan Province, with a total of 5,634 enterprises reported as of January to September 2025, marking an increase of 211 enterprises compared to the same period last year, representing a year-on-year growth of 3.89% [1] - The report indicates that the proportion of Yunnan's industrial enterprises accounts for 1.08% of the national total [1] - The data referenced in the article is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Group 2 - The article lists several publicly listed companies in Yunnan, including Yun Aluminum Co., Ltd., Yunnan Copper Co., Ltd., and others, indicating a diverse industrial landscape [1] - Zhiyan Consulting has published a report titled "2025-2031 China Industrial Cloud Industry Market Deep Assessment and Investment Opportunity Forecast Report," which suggests a focus on future investment opportunities in the industrial sector [1] - The article notes that the criteria for scale industrial enterprises in Yunnan have been updated since 2011, raising the threshold for annual main business income from 5 million yuan to 20 million yuan [1]

证券之星消息，11月19日中药板块较上一交易日下跌1.28%，嘉应制药领跌。当日上证指数报收于 3946.74，上涨0.18%。深证成指报收于13080.09，下跌0.0%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 2.36 | 6.79% | 57.94万 | 1.32亿 | | 000538 | 云南白药 | 56.40 | 0.02% | 5.61万 | 3.16亿 | | 300181 | 佐力药业 | 17.30 | -0.17% | 4.21万 | 7276.54万 | | 000423 | 东阿阿胶 | 48.31 | -0.21% | 3.02万 | 1.46亿 | | 600750 | 江中药业 | 21.94 | -0.27% | 4.99万 | 1.10亿 | | 600436 | 片仔瘦 | 176.21 | -0.39% | 1.12万 | 1.97亿 | | 600285 | 羚锐制药 | 22.16 ...

Market Overview - The Chinese medicine sector experienced a decline of 1.1% on November 18, with Te Yi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Te Yi Pharmaceutical (002728) saw a significant drop of 10.02%, closing at 12.75 [2] - Other notable declines included Zhongsheng Pharmaceutical (002317) down 9.99% and Jiaying Pharmaceutical (002198) down 9.96% [2] - The trading volume for Te Yi Pharmaceutical was 978,300 shares, indicating high activity despite the price drop [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 1.771 billion yuan from institutional investors, while retail investors saw a net inflow of 1.701 billion yuan [2][3] - The data indicates that while institutional investors are pulling back, retail investors are actively buying into the sector [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 14.04 million yuan from institutional investors, while it faced a net outflow of 21.57 million yuan from speculative funds [3] - Lingrui Pharmaceutical (600285) also saw a net inflow of 9.86 million yuan from institutional investors, but faced outflows from both speculative and retail investors [3]